Wyeth’s Profit Likely Rising as Fen-Phen Payments Nearing End

Article in the Washington Post — Wyeth shares could rise more than 20 pct: Barron’s, from Reuters.  Here’s an excerpt: “The newspaper said Wyeth may also be near the end of incurring costs for its discontinued fen-phen diet drug, following a nationwide settlement and $21 billion of charges.”

BGS